HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hirofumi Yamamoto Selected Research

5- chloro- 2- (3- (4- phenyl- 3,6- dihydro- 1(2H)- pyridinyl)propyl)- 4(3H)- quinazolinone

8/2004A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hirofumi Yamamoto Research Topics

Disease

127Neoplasms (Cancer)
11/2022 - 03/2002
85Colorectal Neoplasms (Colorectal Cancer)
06/2022 - 10/2002
39Neoplasm Metastasis (Metastasis)
09/2021 - 02/2004
27Colonic Neoplasms (Colon Cancer)
05/2022 - 05/2005
26Rectal Neoplasms (Rectal Cancer)
11/2022 - 10/2003
13Hepatocellular Carcinoma (Hepatoma)
10/2019 - 05/2003
11Lymphatic Metastasis
07/2021 - 01/2006
9Adenocarcinoma
04/2017 - 08/2003
9Hypoxia (Hypoxemia)
02/2017 - 01/2006
7Carcinoma (Carcinomatosis)
02/2022 - 01/2003
7Wounds and Injuries (Trauma)
11/2021 - 01/2017
6Crohn Disease (Crohn's Disease)
01/2022 - 11/2015
5Hemorrhage
07/2021 - 03/2011
5Thrombosis (Thrombus)
07/2021 - 02/2005
5Inflammation (Inflammations)
05/2021 - 11/2015
5Fibrosis (Cirrhosis)
01/2019 - 08/2003
5Stomach Neoplasms (Stomach Cancer)
11/2017 - 01/2004
5Pain (Aches)
08/2017 - 10/2003
4Liver Cirrhosis (Hepatic Cirrhosis)
05/2022 - 08/2003
4Gastrointestinal Neoplasms (Gastrointestinal Cancer)
07/2021 - 02/2008
4Communicable Diseases (Infectious Diseases)
05/2018 - 06/2014
4Adenoma (Adenomas)
01/2016 - 11/2002
3Postoperative Pain
11/2022 - 04/2014
3Breast Neoplasms (Breast Cancer)
09/2021 - 07/2015
3Heart Failure
07/2021 - 06/2017
3Melanoma (Melanoma, Malignant)
01/2020 - 01/2013
3Hyperthermia
10/2019 - 10/2018
3Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
03/2018 - 06/2014
3Pancreatic Neoplasms (Pancreatic Cancer)
11/2017 - 01/2003
3Nausea
02/2017 - 11/2010
3Diarrhea
01/2017 - 11/2006
3Carcinogenesis
09/2012 - 11/2002
3Neurodegenerative Diseases (Neurodegenerative Disease)
09/2004 - 06/2004
2Intestinal Failure
10/2020 - 01/2019

Drug/Important Bio-Agent (IBA)

20Proteins (Proteins, Gene)FDA Link
08/2021 - 11/2002
14MicroRNAs (MicroRNA)IBA
11/2021 - 09/2012
14Messenger RNA (mRNA)IBA
01/2018 - 08/2003
11Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2018 - 08/2005
10Indicators and Reagents (Reagents)IBA
05/2022 - 04/2007
9Biological ProductsIBA
06/2021 - 01/2003
8Leucovorin (Folinic Acid)FDA Link
01/2018 - 10/2005
8Fluorouracil (Carac)FDA LinkGeneric
01/2018 - 02/2005
8Irinotecan (Camptosar)FDA LinkGeneric
01/2017 - 10/2004
8Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2011 - 02/2004
7Bevacizumab (Avastin)FDA Link
04/2022 - 01/2013
6carboapatiteIBA
02/2022 - 01/2013
6EnzymesIBA
08/2021 - 08/2004
6Biomarkers (Surrogate Marker)IBA
07/2021 - 12/2006
6Membrane Proteins (Integral Membrane Proteins)IBA
06/2021 - 10/2010
6TegafurIBA
01/2018 - 01/2006
5AnticoagulantsIBA
06/2022 - 02/2005
5Peptides (Polypeptides)IBA
11/2021 - 01/2017
56,6'- bis- O- (3- nonyldodecanoyl)- alpha,alpha'- trehaloseIBA
07/2020 - 01/2013
5UracilIBA
01/2018 - 01/2006
5GlycolipidsIBA
08/2013 - 10/2010
4XELOXIBA
04/2022 - 05/2014
4RNA (Ribonucleic Acid)IBA
11/2021 - 02/2004
4Nucleic AcidsIBA
04/2020 - 07/2011
4C-Reactive ProteinIBA
01/2019 - 11/2014
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2019 - 06/2002
4AntibodiesIBA
11/2016 - 01/2013
4Pharmaceutical PreparationsIBA
01/2016 - 06/2004
4Transcription Factors (Transcription Factor)IBA
01/2016 - 10/2011
4SurvivinIBA
01/2015 - 08/2005
3Lysine (L-Lysine)FDA Link
05/2022 - 07/2012
3Carcinoembryonic AntigenIBA
05/2022 - 10/2002
3InterferonsIBA
01/2022 - 01/2007
3Immune Checkpoint InhibitorsIBA
11/2020 - 10/2018
3Small Interfering RNA (siRNA)IBA
08/2020 - 01/2015
3ApatitesIBA
08/2020 - 01/2013
3Cadherins (E-Cadherin)IBA
11/2019 - 06/2007
3Transforming Growth Factors (Transforming Growth Factor)IBA
07/2019 - 07/2012
3Capecitabine (Xeloda)FDA Link
10/2018 - 05/2014
3Reactive Oxygen Species (Oxygen Radicals)IBA
04/2017 - 08/2004
3Calcibiotic Root Canal SealerIBA
01/2016 - 02/2008
3Doxorubicin (Adriamycin)FDA LinkGeneric
05/2013 - 03/2008
3Matrix Metalloproteinases (MMPs)IBA
12/2008 - 01/2007
3AngiopoietinsIBA
10/2007 - 02/2004
3Cyclin D1IBA
08/2006 - 11/2002
2InterleukinsIBA
01/2022 - 01/2016
2OsteopontinIBA
11/2021 - 10/2015
2Collagen Type III (Type III Collagen)IBA
11/2021 - 10/2015
2ThrombinFDA Link
11/2021 - 10/2015
2Amino AcidsFDA Link
11/2021 - 08/2003
2SVVYGLR peptideIBA
11/2021 - 10/2015
2Indocyanine Green (Cardio-Green)FDA LinkGeneric
01/2021 - 01/2018
2AntigensIBA
01/2021 - 01/2018

Therapy/Procedure

57Therapeutics
10/2021 - 03/2002
33Drug Therapy (Chemotherapy)
07/2022 - 01/2006
13Radiotherapy
09/2021 - 11/2006
10Colectomy
12/2021 - 04/2014
7Lymph Node Excision (Lymph Node Dissection)
07/2021 - 03/2011
6Neoadjuvant Therapy
07/2022 - 11/2011
6Adjuvant Chemotherapy
05/2022 - 10/2004
5Chemoradiotherapy
10/2018 - 01/2006
4Splenectomy
05/2009 - 01/2004
3Gastrectomy
11/2017 - 01/2004
3Transplantation
07/2016 - 04/2005
3Combination Drug Therapy (Combination Chemotherapy)
03/2008 - 10/2004
2Ligation
05/2022 - 08/2017